Roivant Sciences ROIV Cash Flow Statement
| Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| —— | -$313.7M-366% | -$166.04M+40.7% | -$223.36M-334% | -$252.38M— | ||
| $638K-55.2% | $691K-76.3% | $921K-81.0% | $1.1M-77.5% | $1.43M-72.7% | ||
| $77.17M-7.6% | $105M+25.5% | $81.82M+14.2% | $82.18M+63.7% | $83.49M+78.7% | ||
| $16.16M+9,891% | -$3.99M— | $3M— | -$11.75M+53.5% | -$165K-101% | ||
| $63.23M— | —— | —— | -$25M+33.5% | —— | ||
| $1.85M-15.3% | $1.85M-15.3% | $1.85M-15.3% | $1.85M-15.3% | $2.19M+153% | ||
| -$252K-230% | -$252K-230% | -$252K-230% | -$252K-230% | $193.25K+132% | ||
| —— | -$8.3M-230% | $3.21M-84.4% | $71K+101% | -$18.4M— | ||
| $21.26M+946% | $21.26M+946% | $21.26M+946% | $21.26M+946% | -$2.51M-201% | ||
| —— | $21.59M+201% | $128.5M+166% | -$19.13M-226% | $12.9M— | ||
| $1.86M-5.5% | $2.53M+47.7% | $1.94M+23.0% | $1.94M+22.9% | $1.97M+9.7% | ||
| $0+100% | —— | —— | —— | -$2.21M— | ||
| -$275K-14.1% | -$786K+61.0% | -$846K+48.0% | -$478K+73.7% | -$241K+88.9% | ||
| -$18.45M— | $2.73M-93.4% | $4.39M— | -$128K-101% | —— | ||
| -$163.82M+5.1% | -$196.48M+5.2% | -$185.66M+30.4% | -$204.38M-6.0% | -$172.57M-59.1% | ||
| $1.26M+55.5% | —— | $7.85M+688% | $4.04M+318% | $811K+132% | ||
| $0-100% | $0-100% | —— | —— | $75M+532% | ||
| $629.5K+897% | $629.5K— | $629.5K— | $629.5K— | -$79K+99.0% | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $1.02B— | ||
| —— | —— | —— | -$1.09B-112,409% | —— | ||
| —— | —— | —— | $208.29M-67.9% | $295.45M— | ||
| -$217.17M— | $118.81M— | $68.29M+3,107% | $30.06M+1,224% | $0— | ||
| $0— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $328.19M+220% | —— | -$187.77M+71.6% | -$177.15M— | ||
| $1.32M— | $430K— | $1.21M-76.1% | $815K+130% | —— | ||
| -$57.79M— | —— | -$1.45M+100.0% | -$1.48B-72.3% | —— | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $1.49M-41.9% | ||
| —— | $8.72M-70.2% | $9.82M-60.8% | $11.06M— | $15.66M— | ||
| $0-100% | -$24.42M— | -$20.96M— | -$2.33M-102% | $14.12M— | ||
| —— | $21.59M+201% | $128.5M+166% | -$19.13M-226% | $12.9M— | ||
| $0— | $0— | $0— | $0-100% | $0— | ||
| $0-100% | —— | —— | —— | $94.13M— | ||
| $16.16M+9,891% | -$3.99M— | $3M— | -$11.75M+53.5% | -$165K-101% | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| $192.56M— | $192.56M— | $192.56M— | $192.56M— | $0— | ||
| -$275K-14.1% | -$786K+61.0% | -$846K+48.0% | -$478K+73.7% | -$241K+88.9% | ||
| -$18.45M— | $2.73M-93.4% | $4.39M— | -$128K-101% | —— | ||
| $3.9M— | $3.9M— | $3.9M— | $3.9M— | $0— | ||
| $1.86M-5.5% | $2.53M+47.7% | $1.94M+23.0% | $1.94M+22.9% | $1.97M+9.7% | ||
| —— | —— | -$5.98M-133% | -$11.08M-98.7% | -$4.23M+90.0% | ||
| $4.42M+5,870% | —— | —— | —— | $74K-90.8% | ||
| $629.5K+897% | $629.5K— | $629.5K— | $629.5K— | -$79K+99.0% | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $1.02B— | ||
| $280.58M— | $280.58M— | $280.58M— | $280.58M— | $0— | ||
| $0-100% | —— | —— | —— | $27.6M-97.9% | ||
| $0— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $8.75M+17.3% | $23.86M+177% | $6.48M-23.3% | $9.53M-24.8% | $7.46M-73.9% | ||
| $48.4M-57.1% | $48.4M— | $48.4M— | $48.4M— | $112.78M+89.0% | ||
| —— | $39.25M— | —— | —— | $0— | ||
| $0-100% | $0-100% | —— | —— | $75M+532% | ||
| —— | $381K— | —— | —— | $380K+4.4% | ||
| $0— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $0-100% | $0— | $0+100% | $0-100% | $23.29M— | ||
| —— | —— | -$14.82M-648% | $44K-61.1% | —— | ||
| -$464K-373% | —— | —— | —— | -$98K+94.5% | ||
| $14.42M— | $14.42M— | $14.42M— | $14.42M— | $0— | ||
| $7.78M— | $7.78M— | $7.78M— | $7.78M— | $0— | ||
| -$165.08M+4.8% | -$191.55M+8.4% | -$193.51M+27.7% | -$208.42M-7.5% | -$173.38M-59.3% | ||
| -$165.08M+4.8% | -$191.55M+8.4% | -$193.51M+27.7% | -$208.42M-7.5% | -$173.38M-59.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Roivant Sciences generate?
- Roivant Sciences (ROIV) generated -$750.3M in operating cash flow over the trailing twelve months.
- What is Roivant Sciences's free cash flow?
- After $14.0M of capital expenditures, Roivant Sciences's free cash flow was -$758.6M over the trailing twelve months, up 10.1% year over year.
- Where does Roivant Sciences's cash flow data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
